In India, Chimeric Antigen Receptor T Cell (CAR-T) Therapy, a gene therapy for the treatment of blood cancer, was successfully performed on Cancer (ACTREC) in the bone marrow transplant department of the Advanced Treatment, Research and Education Center last Friday. Tata Memorial Hospital in Mumbai collaborated with IIT Bombay. The Department of Biotechnology (DBT) under the Ministry of Science and Technology said on Thursday that the central government has allocated Rs 19,915 crore for the first phase I/II clinical trial of CAR-T cells in humans. CAR-T therapy has become a breakthrough in cancer treatment, and global clinical trials have shown promising results in end-stage patients, especially patients with acute lymphoblastic leukemia.
Although it has proven therapeutic potential for cancer patients, this gene therapy is still not available in India. The patient’s CAR-T cell therapy costs Rs. Therefore, the challenge is not only to develop technology on a large scale, but also to reduce costs. And last Friday’s success may be just the first step in this direction. CAR-T cells are designed and manufactured in the Bioscience and Bioengineering (BSBE) department of IIT Bombay.
Subhasis Chaudhuri, Director of IIT Bombay, said: “Our scientists and Tata Memorial Hospital have launched the most advanced cancer treatments. If the trial is successful, it could save millions of lives by providing treatment in India at an affordable cost. .”
The clinical trials of “India’s First” gene therapy were conducted by Dr. Gaurav Narula, Professor of Pediatric Oncology and Health Sciences (Surg Cdr) and his team from TMC Mumbai. The new CAR-T cells that can be used as drugs are manufactured by Professor Rahul Purwar of the Department of Biological Sciences and Bioengineering (BSBE) and his team at IIT Bombay. DBT said in a press release that the design, development and extensive preclinical testing was carried out by IIT-B as a collaborative project with the Tata Memorial Center in Mumbai by two researchers.
This work was partially supported by the Biotechnology Industry Research Assistance Committee (BIRAC). The National Biopharmaceutical Mission under DBT-BIRAC also supports TMC-IIT Bombay in the phase I/II trials of its CAR-T products.
In addition, the National Biopharmaceutical Mission also supports the development of lentiviral vector manufacturing facilities for packaging plasmids, the transfer of modified T cells into the body, cGMP facilities for T cell transduction, and CAR T cell manufacturing facilities. Expand to two other organizations.